Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INTS

Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis

Intensity Therapeutics, Inc. Common stock logo

About Intensity Therapeutics, Inc. Common stock Stock (NASDAQ:INTS)

Advanced Chart

Key Stats

Today's Range
$2.36
$2.79
50-Day Range
N/A
52-Week Range
$0.50
$5.28
Volume
73,559 shs
Average Volume
46,434 shs
Market Capitalization
$8.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Intensity Therapeutics, Inc. Common stock Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

INTS MarketRank™: 

Intensity Therapeutics, Inc. Common stock scored higher than 59% of companies evaluated by MarketBeat, and ranked 727th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Intensity Therapeutics, Inc. Common stock are expected to grow in the coming year, from ($1.18) to ($1.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intensity Therapeutics, Inc. Common stock is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intensity Therapeutics, Inc. Common stock is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intensity Therapeutics, Inc. Common stock has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.50% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.
  • Short Interest Ratio / Days to Cover

    Intensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 27.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Intensity Therapeutics, Inc. Common stock does not currently pay a dividend.

  • Dividend Growth

    Intensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.50% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.
  • Short Interest Ratio / Days to Cover

    Intensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 27.57%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Intensity Therapeutics, Inc. Common stock this week, compared to 0 articles on an average week.
  • Search Interest

    Only 4 people have searched for INTS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Intensity Therapeutics, Inc. Common stock to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.60% of the stock of Intensity Therapeutics, Inc. Common stock is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.

  • Read more about Intensity Therapeutics, Inc. Common stock's insider trading history.
Receive INTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intensity Therapeutics, Inc. Common stock and its competitors with MarketBeat's FREE daily newsletter.

INTS Stock News Headlines

Intensity Therapeutics announces $2.35M public offering
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Intensity Therapeutics files to sell 4.26M shares of common stock
See More Headlines

INTS Stock Analysis - Frequently Asked Questions

Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) announced its quarterly earnings data on Thursday, March, 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01.

Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an IPO on Friday, June 30th 2023. The company issued 3,900,000 shares at a price of $5.00 per share.

Top institutional investors of Intensity Therapeutics, Inc. Common stock include Sapient Capital LLC (6.47%).

Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics, Inc. Common stock investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ).

Company Calendar

Last Earnings
3/13/2025
Today
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INTS
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,412.5%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.96 per share
Price / Book
0.59

Miscellaneous

Free Float
12,295,000
Market Cap
$8.49 million
Optionable
Not Optionable
Beta
4.03
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:INTS) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners